SOST and hyperostosis corticalis generalisata: However, there have been no reports of increased cardiovascular events in sclerosteosis, van Buchem disease, or sclerostin knockout mice [20,66], and there is a lack of scientific evidence suggesting that romosozumab strongly leads to cardiovascular events.